JPRN-UMIN000000962未知未知
Phase II study of neoadjuvant chemotherapy TS-1/CPT-11 for advanced lower rectal cancers - Phase II study of neoadjuvant chemotherapy TS-1/CPT-11 for advanced lower rectal cancers
Dept. Surgery Kyoto University Hospital0 个研究点目标入组 25 人开始时间: 2008年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Excluded are cases with conditions as below: 1) Multiple malignancies to be treated. 2) Previous history of severe drug-induced allergy. 3) Active infectious diseases. 4) Coexistent severe diseases including pulmonary fibrosis, interstitial pneumonia, ileus, uncontrollable diabetes, cardiac dysfunction, hepatic failure, or renal failure. 5) Peritoneal or pleural fluid retention to be drainaged. 6) Symptomatic brain metastases. 7) Active digestive tract bleeding. 8) Severe watery diarrhea. 9) Pregnant. 10) Previous treatment history of radiotherapy.
研究者
相似试验
已完成
不适用
Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for resectable large type 3 or type 4 gastric cancerAdvanced gastric cancerJPRN-UMIN000014332School of Medicine, Keio University40
已完成
不适用
Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07)Breast CancerJPRN-UMIN000010504Department of Surgery Kurume University School of Medicine30
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000008085Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)60
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000012909Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)120
招募中
不适用
PhaseII trial of neoadjuvant chemotherapy with TS-1, Oxaliplatin and Bevacizumab for resectable liver metastases from colorectal cancerResectable colorectal liver metastasesJPRN-UMIN000004706agoya Surgical Oncology Group60